Please login to the form below

Not currently logged in

EUSA founder joins Oxford BioTherapeutics as chairman

Bryan Morton has rich experience in oncology

Oxford Biotherapeutics Bryan MortonOncology-focused biotech Oxford BioTherapeutics has appointed industry veteran Bryan Morton as non-executive chairman.

Morton has 30 years' experience in the life sciences industry, including founding and serving as CEO of oncology specialist EUSA Pharma. This company was later sold to Jazz Pharma in 2012 for $700m.

Prior to founding EUSA in 2005, Morton founded Zeneus Pharma in 2003, before selling the company to Cephalon for $360m.

In addition to his entrepreneurial activities, Morton served as president of Convatec EMEA and spent more than 20 years in various roles at Merck & Co.

“His success in building valuable businesses and knowledge of the cancer space in particular will be important as we look to further develop our pipeline of antibody based cancer medicines to fulfil unmet patient needs,” said Christian Rohlff, CEO and founder of Oxford BioTherapeutics.

28th June 2013


Featured jobs

Subscribe to our email news alerts


Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...